Genetic Susceptibility in Understanding of Pancreatic Ductal Adenocarcinoma Risk: A Decade-Long Effort of the PANDORA Consortium
- PMID: 35506247
- PMCID: PMC9306286
- DOI: 10.1158/1055-9965.EPI-21-1340
Genetic Susceptibility in Understanding of Pancreatic Ductal Adenocarcinoma Risk: A Decade-Long Effort of the PANDORA Consortium
Abstract
Pancreatic cancer, a complex disease, emerges as a severe health problem worldwide and it exhibits a poor prognosis and high mortality. Risk factors associated with sporadic pancreatic cancer remain poorly understood, even less is known about disease prognosis due to its rapid progression. The PANcreatic Disease ReseArch (PANDoRA) consortium, of which the authors are members, was established to coordinate the efforts of different research groups to uncover new genetic factors for pancreatic cancer risk, response to treatment, and patient survival. PANDoRA consortium has contributed to the identification of several low-penetrance risk loci for the disease both by candidate variants approach and genome-wide association studies, including those in cell-cycle and DNA damage response, telomere homeostasis, SCL and ABC transporters, ABO locus variability, mitochondrial metabolism and it participated on collaborative genome-wide association study approach and implementation of a search for functional-based pancreatic cancer risk loci and long noncoding RNAs. Complex studies covering genetic, environmental and microenvironmental factors in the pancreatic cancer onset, progression and its prognosis are warranted.
©2022 The Authors; Published by the American Association for Cancer Research.
Similar articles
-
ABO blood groups and pancreatic cancer risk and survival: results from the PANcreatic Disease ReseArch (PANDoRA) consortium.Oncol Rep. 2013 Apr;29(4):1637-44. doi: 10.3892/or.2013.2285. Epub 2013 Feb 12. Oncol Rep. 2013. PMID: 23403949
-
Genome-wide association study identifies an early onset pancreatic cancer risk locus.Int J Cancer. 2020 Oct 15;147(8):2065-2074. doi: 10.1002/ijc.33004. Epub 2020 May 1. Int J Cancer. 2020. PMID: 32270874
-
Germline genetic variability in pancreatic cancer risk and prognosis.Semin Cancer Biol. 2022 Feb;79:105-131. doi: 10.1016/j.semcancer.2020.08.003. Epub 2020 Aug 18. Semin Cancer Biol. 2022. PMID: 32818625 Review.
-
Common genetic variants associated with pancreatic adenocarcinoma may also modify risk of pancreatic neuroendocrine neoplasms.Carcinogenesis. 2018 Mar 8;39(3):360-367. doi: 10.1093/carcin/bgx150. Carcinogenesis. 2018. PMID: 29309705
-
The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years' experience of association studies to understand the genetic architecture of pancreatic cancer.Crit Rev Oncol Hematol. 2023 Jun;186:104020. doi: 10.1016/j.critrevonc.2023.104020. Epub 2023 May 8. Crit Rev Oncol Hematol. 2023. PMID: 37164172 Review.
Cited by
-
Commentary: Special Issue: Current Understanding of Colorectal and Pancreatic Cancers.Mutagenesis. 2025 Mar 15;40(1):1-3. doi: 10.1093/mutage/geae009. Mutagenesis. 2025. PMID: 38551731 Free PMC article. No abstract available.
References
-
- Gco.iarc.fr [Internet]. Cancer today. 2020 [Accessed 1 March 2022]. Available from: https://gco.iarc.fr/today/fact-sheets-cancers.
-
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017;67:7–30. - PubMed
-
- Oldfield LE, Connor AA, Gallinger S. Molecular events in the natural history of pancreatic cancer. Trends Cancer 2017;3:336–46. - PubMed
-
- Gentiluomo M, Canzian F, Nicolini A, Gemignani F, Landi S, Campa D. Germline genetic variability in pancreatic cancer risk and prognosis. Semin Cancer Biol 2022;79:105–31. - PubMed
-
- Campa D, Rizzato C, Capurso G, Giese N, Funel N, Greenhalf W, et al. Genetic susceptibility to pancreatic cancer and its functional characterisation: the PANcreatic Disease ReseArch (PANDoRA) consortium. Dig Liv Dis 2013;45:95–9. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous